332 related articles for article (PubMed ID: 29332180)
1. CD39-adenosinergic axis in renal pathophysiology and therapeutics.
Kishore BK; Robson SC; Dwyer KM
Purinergic Signal; 2018 Jun; 14(2):109-120. PubMed ID: 29332180
[TBL] [Abstract][Full Text] [Related]
2. The impact of purinergic signaling on renal ischemia-reperfusion injury.
Lu B; Rajakumar SV; Robson SC; Lee EK; Crikis S; d'Apice AJ; Cowan PJ; Dwyer KM
Transplantation; 2008 Dec; 86(12):1707-12. PubMed ID: 19104409
[TBL] [Abstract][Full Text] [Related]
3. The role of the CD39-CD73-adenosine pathway in liver disease.
Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
[TBL] [Abstract][Full Text] [Related]
4. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
Dwyer KM; Kishore BK; Robson SC
Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
[TBL] [Abstract][Full Text] [Related]
5. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H
PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099
[TBL] [Abstract][Full Text] [Related]
6. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
[TBL] [Abstract][Full Text] [Related]
7. Extracellular ATP inhibits IL-1-induced MMP-1 expression through the action of CD39/nucleotidase triphosphate dephosphorylase-1 on human gingival fibroblasts.
Nemoto E; Gotoh K; Tsuchiya M; Sakisaka Y; Shimauchi H
Int Immunopharmacol; 2013 Nov; 17(3):513-8. PubMed ID: 23941770
[TBL] [Abstract][Full Text] [Related]
8. Extracellular generation of adenosine by the ectonucleotidases CD39 and CD73 promotes dermal fibrosis.
Fernández P; Perez-Aso M; Smith G; Wilder T; Trzaska S; Chiriboga L; Franks A; Robson SC; Cronstein BN; Chan ESL
Am J Pathol; 2013 Dec; 183(6):1740-1746. PubMed ID: 24266925
[TBL] [Abstract][Full Text] [Related]
9. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.
Covarrubias R; Chepurko E; Reynolds A; Huttinger ZM; Huttinger R; Stanfill K; Wheeler DG; Novitskaya T; Robson SC; Dwyer KM; Cowan PJ; Gumina RJ
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1809-20. PubMed ID: 27417582
[TBL] [Abstract][Full Text] [Related]
10. Role of extracellular ATP metabolism in regulation of platelet reactivity.
Birk AV; Broekman MJ; Gladek EM; Robertson HD; Drosopoulos JH; Marcus AJ; Szeto HH
J Lab Clin Med; 2002 Sep; 140(3):166-75. PubMed ID: 12271274
[TBL] [Abstract][Full Text] [Related]
11. The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.
Roberts V; Lu B; Rajakumar S; Cowan PJ; Dwyer KM
Purinergic Signal; 2013 Jun; 9(2):135-43. PubMed ID: 23188420
[TBL] [Abstract][Full Text] [Related]
12. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.
Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC
Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury.
Guckelberger O; Sun XF; Sévigny J; Imai M; Kaczmarek E; Enjyoji K; Kruskal JB; Robson SC
Thromb Haemost; 2004 Mar; 91(3):576-86. PubMed ID: 14983235
[TBL] [Abstract][Full Text] [Related]
14. Crowding within synaptic junctions influences the degradation of nucleotides by CD39 and CD73 ectonucleotidases.
Rahmaninejad H; Pace T; Chun BJ; Kekenes-Huskey PM
Biophys J; 2022 Jan; 121(2):309-318. PubMed ID: 34922916
[TBL] [Abstract][Full Text] [Related]
15. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.
Serra S; Horenstein AL; Vaisitti T; Brusa D; Rossi D; Laurenti L; D'Arena G; Coscia M; Tripodo C; Inghirami G; Robson SC; Gaidano G; Malavasi F; Deaglio S
Blood; 2011 Dec; 118(23):6141-52. PubMed ID: 21998208
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
[TBL] [Abstract][Full Text] [Related]
17. Purinergic signaling in liver disease.
Vaughn BP; Robson SC; Longhi MS
Dig Dis; 2014; 32(5):516-24. PubMed ID: 25034284
[TBL] [Abstract][Full Text] [Related]
18. Extracellular ATP signaling and clinical relevance.
Dou L; Chen YF; Cowan PJ; Chen XP
Clin Immunol; 2018 Mar; 188():67-73. PubMed ID: 29274390
[TBL] [Abstract][Full Text] [Related]
19. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury.
Eckle T; Füllbier L; Wehrmann M; Khoury J; Mittelbronn M; Ibla J; Rosenberger P; Eltzschig HK
J Immunol; 2007 Jun; 178(12):8127-37. PubMed ID: 17548651
[TBL] [Abstract][Full Text] [Related]
20. Structural and functional characterization of engineered bifunctional fusion proteins of CD39 and CD73 ectonucleotidases.
Zhong EH; Ledderose C; De Andrade Mello P; Enjyoji K; Lunderberg JM; Junger W; Robson SC
Am J Physiol Cell Physiol; 2021 Jan; 320(1):C15-C29. PubMed ID: 33052071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
